We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$955M
AUM Growth
+$74.9M
Cap. Flow
+$18.7M
Cap. Flow %
1.96%
Top 10 Hldgs %
28.16%
Holding
94
New
8
Increased
32
Reduced
32
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.3M
2
BDX icon
Becton Dickinson
BDX
+$9.95M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.64M
4
TMO icon
Thermo Fisher Scientific
TMO
+$8.62M
5
MDT icon
Medtronic
MDT
+$8.09M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$13M
3
CI icon
Cigna
CI
+$10.1M
4
PFE icon
Pfizer
PFE
+$9.23M
5
ELV icon
Elevance Health
ELV
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 98.85%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
76
Guardant Health
GH
$22.3B
$3.22M 0.34%
65,000
-30,000
-32% -$1.54M
EXAS
77
DELISTED
Exact Sciences
EXAS
$2.64M 0.28%
76,000
– –
NTLA icon
78
Intellia Therapeutics
NTLA
$1.69B
$2.64M 0.28%
50,000
– –
NKTX icon
79
Nkarta
NKTX
$165M
$2.52M 0.26%
200,000
– –
PHAT icon
80
Phathom Pharmaceuticals
PHAT
$696M
$2.49M 0.26%
235,210
– –
ARVN icon
81
Arvinas
ARVN
$587M
$2.49M 0.26%
50,000
– –
NVCR icon
82
NovoCure
NVCR
$2.03B
$2.47M 0.26%
35,000
-25,000
-42% -$1.95M
IONS icon
83
Ionis Pharmaceuticals
IONS
$9.31B
$2.21M 0.23%
50,000
– –
NKTR icon
84
Nektar Therapeutics
NKTR
$2.53B
$2.07M 0.22%
36,667
– –
TXG icon
85
10x Genomics
TXG
$7.86B
$2.04M 0.21%
+75,000
New +$2.86M
HCAT icon
86
Health Catalyst
HCAT
$132M
$1.59M 0.17%
180,000
– –
STXS icon
87
Stereotaxis
STXS
$145M
$1.49M 0.16%
797,330
– –
EPIX
88
DELISTED
ESSA Pharma
EPIX
$1.35M 0.14%
375,000
– –
RIGL icon
89
Rigel Pharmaceuticals
RIGL
$775M
$893K 0.09%
122,508
– –
RPID icon
90
Rapid Micro Biosystems
RPID
$87.3M
$876K 0.09%
300,000
– –
ALGN icon
91
Align Technology
ALGN
$12.3B
– –
-18,000
Closed -$4.26M
MYOV
92
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-310,000
Closed -$3.85M
ONEM
93
DELISTED
1Life Healthcare
ONEM
– –
-375,250
Closed -$2.94M
AERI
94
DELISTED
Aerie Pharmaceuticals
AERI
– –
-562,350
Closed -$4.22M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rhenman & Partners Asset Management held 94 positions worth $955M, up 8.5% from $880M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management's Q3 2022 filing shows 8 new, 32 increased, 32 reduced and 4 closed positions. Its largest new stake was Insulet: 29,000 shares worth $7.5M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q3 2022 buy was Insulet: 29,000 shares worth $7.5M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q3 2022, an estimated $11.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Align Technology in Q3 2022, selling an estimated $4.26M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $955M portfolio in Q3 2022.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q3 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 8.5% quarter-over-quarter to $955M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.